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Purpose: Chagas disease (CD) has become a global
health issue mainly due to migration. Germany lacks
surveillance data and is home to a large Latin
American immigrant population. Recognising that
Bolivia is the country with the highest CD prevalence in
Latin America, this cross-sectional, descriptive pilot
study investigated CD and associated factors among
citizens of Bolivian origin living in Munich, Germany.
Methods: Participants completed a questionnaire in
order to collect socioeconomic and health-related data.
In addition, serology was performed. In case of
positive serological tests, PCR diagnostic and clinical
staging together with disease management was
initiated. Qualitative research was conducted to identify
personal and community barriers as well as strategies
to increase CD awareness among the population at
risk.
Results: Between June 2013 and June 2014, 43
people from Bolivia (or descendants) were enrolled.
A total of 9.3% (4/43), of whom two women were of
childbearing age, tested seropositive (ELISA and IFAT),
and one also by PCR. For 2/4 positive participants,
clinical evaluation was performed and the
indeterminate form of CD was diagnosed. Knowledge
about CD symptoms and ways of transmission were
completely absent among 55.8% (24/43, 2/4 with CD)
and 30.2% (13/43, 1/4 with CD) of participants,
respectively. A total of 27.9% (12/43, 0/4 with CD) of
participants had donated blood prior to the study,
whereas 62.8% (27/43, 3/4 with CD) were motivated to
donate blood in the future. The qualitative research
identified lack of knowledge as well as stigma and
fears related to CD.
Conclusions: Despite the small number of
participants, the prevalence of CD as well as the
potential risk of non-vectorial transmission was
alarming. Campaigns adapted for Latin American
migrants as well as control strategies should be
developed and put in place in order to prevent non-
vectorial transmission and actively detect cases of CD
in Germany.
INTRODUCTION
Chagas disease (CD) is a potentially life-
threatening infection caused by the proto-
zoan Trypanosoma cruzi. Current estimations
are 6–7 million infected humans worldwide.1
An initial acute phase of CD is usually fol-
lowed by a lifelong asymptomatic chronic
phase. About 30% of chronically infected
persons develop organic dysfunctions, mostly
cardiac and intestinal manifestations such as
dilative cardiomyopathy or megacolon.2
Twenty-one Latin American (LA) countries
are endemic for CD, and Bolivia is by far the
most affected.1 However, owing to the
increased population mobility, CD has
become an international health issue.1 3 In
2012, the WHO launched the document
“Accelerating work to overcome the global
impact of neglected tropical diseases
Strengths and limitations of this study
▪ Previously undetected cases of Chagas disease
—especially among women of childbearing age
—were added to the few documented cases in
Germany and treatment was initiated.
▪ Challenges for health professionals and for the
health system to reach, diagnose and treat the
at-risk population in Germany were evaluated.
▪ The need for developing and implementing
control strategies for Chagas disease in Germany
is clearly illustrated.
▪ The number of individuals in the cohort is small
and not representative of the total Bolivian popu-
lation in Munich or Germany. The most vulner-
able group—undocumented Bolivian migrants—
could not be reached. Thus, the prevalence of
Chagas disease is probably underestimated and
all results of this study have to be interpreted
carefully.
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(NTDs)”,4 which inspired the London Declaration on
NTDs.5
Vector-borne transmission has been the most common
way of infection in endemic areas. In non-endemic
countries without vectorial transmission, the main risks
have been blood transfusions,6 organ transplantations7
and mother-to-child transmission.8 9 By 2009, only 4290
of the estimated 68 000–122 000 people with CD in
Europe had been diagnosed, being the rate of under-
diagnosis in Germany is alarmingly high.10 In some
countries like France, Italy, Spain and Switzerland, epi-
demiological and preventive studies have already been
conducted.11–15 The only CD epidemiological investiga-
tion in Germany took place in 1997 in Berlin, where 2
of 100 persons were diagnosed.16 In 2011, Germany had
154 160 registered LA migrants.17 Given an estimated
CD prevalence of between 1.3 and 1.7% in this popula-
tion group10 2004 to 2621 infections could be expected.
However, this rough estimation probably underestimates
the number; LA migrants without legal status and the
growing number of LA migrants moving mainly from
Spain to Germany in the past years have not been taken
into account (General Consulate of the Plurinational
State of Bolivia in Madrid, Spain; personal communica-
tion). This alarming lack of CD epidemiological infor-
mation in Germany suggests limited knowledge about
CD in key groups, such as the affected population itself,
healthcare professionals and decisionmakers, and inad-
equate prevention and management of CD. Control of
transfusional, transplantational and congenital transmis-
sion of CD in Germany is still insufficient in the context
of the European Union recommendations and protocols
of other European countries.18–20 In Spain, serological
screening for population at risk of T. cruzi infection has
been implemented by law since 2005,21 and in the USA
since 2007.22 In Germany, however, blood donors are
only asked if they are suffering from any parasitic infec-
tion at present; CD is mentioned, but guidelines recom-
mend no serological screening for people at risk. Only
travellers who visited endemic countries within the previ-
ous 6 months are excluded from donating blood23 and
no routine screening is performed for pregnant women
from endemic countries.
The following has been designed as a pilot study,
which could be useful for further research and control
of the disease, in preparation for a national project
called ‘ELCiD‘ (detection and guidance of patients with




The objectives of this cross-sectional, descriptive pilot
study were:
1. To detect previously undiagnosed cases and deter-
mine the prevalence of CD in a cohort of the
Bolivian community living in Munich
2. To evaluate the possibility of the congenital, transfu-
sional and transplantational risk of T. cruzi infection
transmission
3. To describe the knowledge, feelings and attitudes
related to CD, at the personnel and community level,
of people from Bolivia living in Munich
4. To identify possible strategies to overcome barriers to
T. cruzi infection prevention and access to healthcare
to reach at-risk populations in Germany.
Setting and participants
The study took place in the outpatient clinic of the
Division of Infectious Diseases and Tropical Medicine
(DIDTM) in Munich, Germany. Participants were
recruited through (1) dissemination of informative leaf-
lets, (2) informative presentations at local Bolivian
meeting points (eg, Bolivian consulate) and events
within the local Bolivian community, (3) social media, as
well as (4) the outpatient clinic of DIDTM and family
doctors’ offices. Regarding inclusion criteria, all citizens
of Bolivian origin living in the commuter belt (urban
railway) of Munich that came to the LMU and gave
written informed consent were included. Participants
under the age of 18 years were included via written
informed consent from their parents. Citizens of
Bolivian origin who had neither been in Bolivia nor had
a Bolivian mother, and all persons lacking the capacity
to give informed consent were excluded. All investiga-
tion was conducted according to the principles
expressed in the Declaration of Helsinki and participa-
tion was free of charge.
Questionnaires and qualitative research
All participants completed a questionnaire in order to
collect socioeconomic and medical data (see online
supplementary appendix). All documents were in
German and Spanish, and a bilingual (Spanish-German)
medical doctor was available for assistance at all times.
Concerning qualitative research, two semistructured
interviews, a triangular group and one Participatory
Action Research (PAR) activity with seven participants
was carried out. Qualitative research was conducted in a
total of 12 participants. Selection criteria were: those
participants in the study who wanted to be interviewed,
prior to as well as after performing the serological test.
The PAR consisted of an informative workshop about
CD given by a medical doctor. All activities were
recorded, transcribed and underwent quality control.
Open Code 4.02 software was employed for the analysis.
Methodological (within-method) and investigator tri-
angulation was performed by three researchers.
CD diagnosis
Two independent serological tests were performed:
in-house-ELISA25 and in-house-IFAT.26 Only if both test
results were concordant were they considered positive or
negative. Discordant results should be dealt with indi-
vidually and solved using a third serological test as well
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as external quality control. After diagnosis, two different
PCR tests were performed: a conventional PCR27 and a
real-time PCR (Dia.Pro—Diagnostic Bioprobes Srl, Sesto
San Giovanni, Italy) test. For external quality control, all
positive and 10% of all negative samples were sent to the
Spanish reference laboratory for CD (National Centre of
Microbiology, ISCIII).28 In summary, positive samples
were detected using five different serological methods
and additionally tested with three independent PCRs,
performed in two different laboratories. Negative
samples were confirmed with a minimum of two diverse
serological tests at DIDTM, and 10% of negative samples
were confirmed with three additional serological tests at
ISCIII.
Staging and management of CD
Participants diagnosed with CD were offered specialised
clinical management by a medical doctor. In order to
detect visceral involvement of CD, a complete history as
well as physical examination, further laboratory tests, a
resting ECG and cardiac ultrasound was performed. All
CD-positive patients were counselled not to donate
blood or organs, and screening was offered to their rela-
tives. Positive participants were offered antiparasitic
treatment based on the WHO recommendations.29 30
Benznidazole was used as the first-line medication and
was provided by the WHO. During treatment, close
monitoring was performed. All positive participants were
offered yearly follow-up visits including history, physical
examination and an ECG.
Statistical analyses
Data were entered via double data entry into tables
(Microsoft Excel, V.14.3.1). Individual data were analysed
using STATA (V.11). For calculation of p values, χ2 and
Student’s t-tests were used, where appropriate. If data
were found to be skewed, a Mann-Whitney rank sum test
was used. p Values of <0.05 were considered statistically
significant. Knowledge about CD symptoms was grouped
into categories: ‘none’, ‘poor’ (one symptom named),
‘intermediate’ (more than one symptom named) and
‘good’ (three frequent symptoms named). Knowledge
about ways of transmission was grouped into categories
such as ‘none’, ‘poor’ (one way of transmission named),
‘intermediate’ (2–3 ways named) and ‘good’ (4–5 ways
named).
RESULTS
Between June 2013 and June 2014, 43 participants were
enrolled, of whom 29 (67.4%) were female. The mean
age was 39 years (SD 17.2 years), range 7–76 years. All
participants possessed a valid German residency permit
and were of Bolivian (22/43; 51.2%), German (20/43;
37.2%), Spanish (4/43; 9.3%) and Italian (1/43; 2.3%)
nationalities. Four participants possessed dual citizen-
ship (German and Bolivian). The mean duration of stay
outside of Latin America was 19 years (SD 13.7 years).
Emigration from Bolivia generally occurred when the
participants were young adults (mean 22 years, SD 2.2).
Those who were born in Germany and never went to
Bolivia were not included in this analysis; most of them
were children.
CD prevalence and association with socioeconomic factors
There were no discrepancies in any serological tests per-
formed at DIDTM and ISCIII. Four participants (9.3%,
CI 0.26% to 18.35%) tested positive for CD (three
women and one man), table 1. Two of these women
were of childbearing age and wanted to get pregnant.
One woman was also positive by PCR. The only signifi-
cant correlations with testing CD positive and the socio-
economic factors were a higher risk for participants of
rural origin (p=0.017) and participants born to a
mother with CD (p=0.003).
Clinical evaluation and management of CD
All positive participants were offered a clinical evaluation
as well as treatment (where appropriate), free of charge.
Only one CD-positive patient (70 years, male) denied
the diagnosis and refused further follow-up. One posi-
tive female participant had moved abroad (Switzerland)
and planned to get clinical evaluation and treatment
there. The remaining two positive female participants
consisted of a mother (46 years; the only PCR-positive
participant) and her daughter (24 years). During clin-
ical evaluation, no symptoms or findings consistent with
organ involvement were found and both were diagnosed
with the indeterminate stage of CD. Both were treated
with benznidazole (5 mg/kg per day for 60 days) and
tolerated treatment well without adverse events. The ini-
tially positive PCR was negative when repeated 3 months
after treatment.
Attitudes towards blood/organ donation and medical
access
Most of the participants were motivated to donate blood
(27/43; 62.8%; 3/4 with CD) and organs (23/43;
53.5%; 3/4 with CD). Nearly all participants had access
to regular healthcare in Germany (38/43; 88.4%; 3/4
with CD); five did not answer this question (table 2).
Knowledge about CD
Only 30 participants (69.8%; 3/4 with CD) had previ-
ously heard about CD and 24 (55.8%; 2/4 with CD) had
no knowledge of CD symptoms. The possible presence
of CD without symptoms was falsely denied by two parti-
cipants; one of them had CD. Most of the participants
(40/43; 93.0%; 4/4 with CD) had never undergone a
CD test before (table 3).
Qualitative research
Knowledge about CD
Participants focused mainly on insect and congenital
transmission table 4. Otherwise, large confusion and a
Navarro M, et al. BMJ Open 2017;7:e013960. doi:10.1136/bmjopen-2016-013960 3
Open Access




T. cruzi−: n=39 (%)
Participants tested
T. cruzi+: n=4 (%)
Sex
Female 29 (67.4) 26 (66.7) 3 (75.0)
Male 14 (32.6) 13 (33.3) 1 (25.0)
Country of birth
Bolivia 29 (67.4) 26 (66.7) 3 (75.0)
Germany 12 (27.9) 12 (30.8) 0
Peru 1 (2.3) 1 (2.6) 0
Argentina 1 (2.3) 0 1 (25.0)
Main habitation in Bolivia
La Paz 15 (34.8) 15 (38.5) 0
Cochabamba 10 (23.3) 7 (17.9) 3 (75.0)
Santa Cruz 2 (4.7) 2 (5.1) 0
Sucre/Chuquisaca 1 (2.2) 1 (2.6) 0
Potosí 2 (4.7) 2 (5.1) 0
Oruro 3 (7.0) 3 (7.7) 0
Tarija 2 (4.7) 1 (2.6) 1 (25.0)
Bolivian mothers only 8 (18.6) 8 (20.5) 0
Reason for migration to Europe
Work 4 (9.3) 3 (7.7) 1 (25.0)
Studies 19 (44.2) 17 (43.6) 2 (50.0)
Relationship/marriage 6 (15.0) 5 (12.8) 1 (25.0)
Family 8 (18.6) 8 (20.5) 0
Other 6 (14.0) 6 (15.4) 0
Area of residence in Latin America
Urban (>10 000 inhabitants) 36 (83.7) 34 (87.2) 2 (50.0)
Rural (<10 000 inhabitants) 4 (9.3) 2 (5.1) 2 (50.0)
No answer 3 (7.0) 3 (7.7) 0
Material of house during childhood
Stone or cement 26 (60.5) 25 (64.1) 1 (25.0)
Adobe 10 (23.3) 8 (20.5) 2 (50.0)
Other material 7 (16.3) 6 (15.4) 1 (25.0)
‘Vinchuca’-bugs at home
Yes 11 (25.6) 9 (23.1) 2 (50.0)
No 32 (74.4) 30 (76.9) 2 (50.0)
Highest educational level
No school completed 1 (2.3) 1 (2.6) 0
Primary school 2 (4.7) 2 (5.1) 0
Secondary school 9 (20.9) 7 (18.0) 2 (50.0)
Apprenticeship 12 (27.9) 12 (30.8) 0
University 19 (44.2) 17 (43.6) 2 (50.0)
Parents’ highest level of education
No school completed 1 (2.3) 0 1 (25.0)
Primary school 2 (4.7) 1 (2.6) 1 (25.0)
Secondary school 8 (18.6) 7 (18.0) 1 (25.0)
Apprenticeship 12 (27.9) 11 (28.2) 1 (25.0)
University 20 (46.5) 20 (51.3) 0
Chagas disease among relatives
No information 16 (37.2) 17 (43.6) 1 (25.0)
No infected relative 16 (37.2) 15 (38.5) 1 (25.0)
Mother 4 (9.3) 2 (5.1) 2 (50.0)
Father 2 (4.7) 2 (5.1) 0
Brother/sister 1 (2.3) 1 (2.6) 0
Others (grandparents, uncle) 4 (9.3) 2 (5.1) 0
CD, Chagas disease; T. cruzi, Trypanosoma cruzi.
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lack of knowledge about other mechanisms of transmis-
sion were reported (Verbatim 1).
All participants knew that symptoms could appear
after several years. In general, there was a lot of confu-
sion and lack of understanding on the clinical manifesta-
tions (Verbatim 2).
Participants gathered information about CD mainly
from friends, relatives and attending physicians, as
well as from the internet, press and information
received in their home countries. Bolivian associations
and the media stood out as being primary resources
(Verbatim 3).




T. cruzi−: n=39 (%)
Participants tested
T. cruzi+: n=4 (%)
Attitude towards blood donation
Disposed to donate 27 (62.8) 24 (61.5) 3 (75.0)
Not disposed to donate 6 (14.0) 5 (12.8) 1 (25.0)
No decision 10 (23.3) 10 (25.6) 0
Former blood donations
Donation in past 12 (27.9) 12 (30.8) 0
No donation in past 31 (72.1) 27 (69.2) 4 (100.0)
Former received transfusions
Transfusion received 6 (14.0) 5 (12.8) 1 (25.0)
No transfusion received 37 (86.1) 34 (87.2) 3 (75.0)
Attitude towards organ donation after death
Disposed to donate organs 23 (53.5) 20 (51.3) 3 (75.0)
Not disposed to donate organs 11 (25.6) 10 (25.6) 1 (25.0)
No decision 9 (20.9) 9 (23.1) 0
Access to medical services in Germany
Access without problems 38 (88.4) 35 (89.7) 3 (75.0)
No answer 5 (11.6) 4 (10.3) 1 (25.0)
Type of health insurance in Germany
German public/private insurance 38 (88.4) 35 (89.7) 3 (75.0)
Insurance of other EU country 2 (4.7) 1 (2.6) 1 (25.0)
No answer 3 (7.0) 3 (7.7) 0
EU, European Union; T. cruzi, Trypanosoma cruzi.




T. cruzi−: n=39 (%)
Participants tested
T. cruzi+: n=4 (%)
Previously received information about Chagas disease
Information received in past 30 (69.8) 27 (69.2) 3 (75.0)
No information received 13 (30.2) 12 (30.8) 1 (25.0)
Knowledge about three frequent symptoms of chronic Chagas disease
None 24 (55.8) 22 (56.4) 2 (25.0)
Little knowledge 8 (18.6) 7 (18.0) 1 (25.0)
Intermediate knowledge 6 (14.0) 6 (15.4) 0
Good knowledge 5 (11.6) 4 (10.3) 1 (25.0)
Possibility of Chagas disease with absence of symptoms
Yes, possible 23 (53.5) 21 (53.9) 2 (50.0)
Not possible 2 (4.7) 1 (2.6) 1 (25.0)
No knowledge 18 (41.9) 17 (43.6) 1 (25.0)
Knowledge about ways of transmission of Chagas Ddsease
None 13 (30.2) 12 (30.8) 1 (25.0)
Little knowledge 12 (27.9) 10 (25.6) 2 (50.0)
Intermediate knowledge 14 (32.6) 14 (35.9) 0
Good knowledge 4 (9.3) 3 (7.7) 1 (25.0)
Previously tested for Chagas disease
Tested with positive result 0 0 0
Tested with negative result 3 (7.0) 3 (7.7) 0
No test performed 40 (93.0) 36 (92.3) 4 (100.0)
CD, Chagas disease; T. cruzi, Trypanosoma cruzi.
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Participants’ responses confirmed that there is a lot of
lack of knowledge about CD. They considered it highly
important to inform about CD at meeting points, such
as Bolivian associations, sports events and others. The
most effective ways to inform people were audio-visual
material, leaflets, via radio; and the key points to focus
on were the Spanish parish and the Evangelic Latin
Church. It was emphasised that adequate medical infor-
mation and the help of the health system to encourage
people to undergo screening must accompany these
activities (Verbatim 4).
Barriers and facilitators of access to the health system
The obstacles for access to the health system were
mainly structural and psychosocial factors, as well as
living and working conditions (Verbatim 5).
Participants reported that it was not possible to have a
health insurance card without having a contract of




1 It is a parasite that is in the blood, right? (…) it is transmitted because





2 Well, I know that… it is the stomach, the heart and […], if I am not




3 … but the fact that these two or three Bolivian groups have
approached us, they are settled, associated, this has helped to raise






4 I believe that leaflets, with pictures and a bit of information, help quite
a lot. We heard you talking about Chagas, and, I mean, I didn’t care
much [….]. But if a paper is sent to me…not very long, because when
you see a lot of information, you take it and throw it away, right? And
then it is like, you put it in your pocket, you take it out and take a look










6 Yes, without the health card, they won’t see you, of course.





7 They treat me very nicely, I have a general practitioner who speaks
Spanish, the most important thing is that they are always looking after




8 Bolivian man told me about it and I told him: Let’s go! They are giving
treatment for free, look at the opportunity they are giving us! And he
wanted to go but he also told me: “Ok, we need to go but you need
time and with my job, what I am going to do? If they call me to work




9 They are 60 already and they don’t…until now, they didn’t have any




10 There is a lack of willingness too, right? They are not interested, that




11 [People go to see the doctor] when they are almost dying… [laughs]. Woman
Age: 44
Cochabamba
12 But… it is the fear with children, too […] but I don’t know what are the
odds that I may transmit the disease to my girl, and, if it is possible,




13 Of course, because I have travelled a lot around the country, there is
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employment, as well as displaying a lack of knowledge
about social resources and immigrant rights in Germany
(Verbatim 6).
Generally, there was a high level of satisfaction with
the German health system, the physicians being seen as
professionals with knowledge about CD (except in one
reported case). The individual medical assistance stood
out positively, especially when the healthcare profes-
sionals spoke Spanish (Verbatim 7).
The precarious working conditions and long working
days were described as making it difficult to find a
medical consultation compatible; attending a medical
consultation could mean an economic loss or even
unemployment for the patient (Verbatim 8).
Other barriers included: low acknowledgement of the
risk of dying from CD (Verbatim 9); lack of interest and
volition of LA people to approach a physician (Verbatim
10); and the culture of attending a doctor only in urgent
situations (Verbatim 11). The participants pointed out
that in combination with the ignorance about CD, these
barriers impede access to the health system.
The most important factors to deciding to perform
screening were: fear of transmitting CD to someone’s
own children (Verbatim 12), having relatives or friends
suffering from CD, having been in contact with the
vector in the past or having lived in rural areas
(Verbatim 13).
DISCUSSION
The prevalence of T. cruzi infection varies according to
the locations and the methodology used to reach the
population at risk. The prevalence in our study was
9.3%, much lower than in cohorts with previous infor-
mational campaigns in Spain and Switzerland (20.9–
26.2%)11 13 and in Tropical Medicine Centers in Spain
(higher than 30%; due to a selection bias because many
patients who attend these consultations already know or
have a high suspicion of suffering from CD).8 20 31
However, it is similar to one study performed among
Bolivian blood donors (10.2%)32 and in a similar study
performed in Spain.33 The reason could be that the
profile of participants is similar in these cohorts, as
several participants came from regions with a low preva-
lence of CD.
Nevertheless, the strength of this initiative lies in the
detection of new patients. Up to 93% of participants
(including those with positive serology) had never been
tested for CD previously. Probably, in the absence of this
programme, the four new patients would still be
unaware of their serological status. In fact, Europe is
facing a CD underdiagnosis crisis with higher than 95%
of at-risk communities not being tested.10 This highlights
the need for additional public health measures involving
communities from endemic areas.
According to the German Census of 2011,17 2703
persons with Bolivian nationality were registered in
Germany. Of those, 460 were in Bavaria and 182 in
Munich. The number of German citizens of Bolivian
origin in Munich or undocumented Bolivian migrants is
unknown. Of the registered Bolivian citizens in Munich,
18/89 (20.2%) with Bolivian nationality and 4/93
(4.3%) with dual citizenship could be included in this
study. Previous studies indicate that Bolivian migrants
without a valid residency permit and health insurance
have the highest rate of CD,34 but despite serious efforts
to reach this population, none could be included.
Possible reasons could be fear of detection, no attend-
ance of regular medical services, time incompatibility
due to work or lack of knowledge about the possibility of
treatment for CD, among others, as observed in other
non-endemic countries.35 36 With this in mind, the
prevalence of CD is probably underestimated and all
results of this study have to be cautiously interpreted. In
addition, the migration of LAs from the Southern to
Central Europe has considerably increased in the past
few years.
In Germany, treatment of patients with CD poses
several challenges: few centres disseminate knowledge
regarding the treatment of CD, as national guidelines
for screening and treatment are not available. Also, the
two drugs currently in use (benznidazole and nifurti-
mox) are neither registered nor available in Germany.
Thus, they are difficult to obtain and have to be used
unlicensed. Although it is possible to receive those drugs
free of charge from the WHO, during this study their
import posed difficulties at DIDTM. It took lengthy cor-
respondence by the medical doctors in charge of treat-
ment with the legal department of DIDTM and the
WHO due to a lack of information about legal implica-
tions of this process. The absence of specific treatment
in Germany needs to be addressed by the scientific com-
munity and the health authorities. Structural issues
clearly need to be improved as, for example, has been
highlighted in the USA.22
There is a serious lack of epidemiological data on CD
in Germany, with only one study previously published.16
Lack of awareness of CD among politicians as well as
healthcare personnel, lack of guidelines, treatment
know-how, screening measurements and effective trans-
mission control may be some of the consequences of
this absence of epidemiological data.22 There is an
urgent need for broader studies in Germany including
more regions/subjects and a higher representativeness
of the study population.
Owing to the small number of positive cases in this
study, correlations of socioeconomic factors with CD
were not significant. However, participants of rural
origin or born from a mother with CD had a higher risk
of CD, which is in concordance with previously con-
ducted studies.13 37 38
Adequate screening and transmission control mea-
sures for CD in Germany are currently lacking.
Healthcare professionals lack awareness of this disease,
and thus few tests on CD are undertaken. There is no
screening for pregnant women at risk, nor for blood or
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organ donors.18 Coupled with the high willingness to
donate blood or organs among the participants, and the
women of childbearing age diagnosed through this ini-
tiative (two of four of the diagnosed participants), this is
alarming. There is no data of non-vectorial transmission
of CD in Germany. However, in several other
non-endemic countries, transmission through transfu-
sion, organ transplantation or congenitally has been
documented.18
A serious lack of information about CD among
Bolivian migrants living in Munich was found from the
questionnaire and qualitative research, in agreement
with the findings in Spain.8 Participants obtained infor-
mation on CD mainly through relatives, friends, the
media and Bolivian associations. Religious meetings and
other social gatherings were mentioned as effective
places to disseminate information and graphic materials.
These channels have been used successfully in other
European countries to reach the population at risk.12 14
The perception of risk for CD varied depending on the
existence of affected relatives, on past experiences in
Bolivia and on the presence/absence of symptoms.34
Some cases of discrimination were given in reference to
CD, regarding both the social and work environments,
as mentioned in endemic countries.39 Some of the bar-
riers to getting information about CD in Munich,
observed in this study, were also mentioned in other
non-endemic countries, such as lack of knowledge, fear
and barriers to accessing healthcare services.11 22 35 40
The German healthcare system was generally well
respected by participants. However, long waiting lists
were seen as a disadvantage due to economic cuts.
Problems to coordinate personal and professional lives
provided barriers to access healthcare services.
Discrimination was felt by one of the participants, both
for being affected by CD and for being a newly arrived
migrant, which also hinders access to healthcare.
Our small cohort reflects the difficulties in reaching
the population at risk when the host country has cultural
differences. In order to be effective, future information
and awareness campaigns should investigate precisely
the previous knowledge and perceptions of CD of the
target population as well as the sources of information
they employ. After this initiative, participants were less
reluctant to reach other participants and encourage
them to join the study. This information can be useful
for future studies in Germany as well as in other
European countries, especially for initiatives or pro-
grammes like ELCiD,24 which could increase case detec-
tion for CD in non-endemic countries and should be
integrated in the common practices of public health
programmes.
All mentioned public health measures are critical in
order to face the United Nations development goal 3.3
(by 2030, end the epidemics of AIDS, tuberculosis,
malaria and neglected tropical diseases…)41 with the
renewed challenge to detect and eliminate CD in
Germany and in the rest of Europe.
Summing up the limitations of this study, clearly the
small number of participants has to be mentioned. Also,
the most vulnerable population for CD—Bolivian
migrants without a valid residency permit or health
insurance—could not be reached and correlations of
socioeconomic factors with CD were impaired due to
the small number of positive cases. Thus, the data of this
study cannot be generalised and have to be debated very
cautiously, especially in the international context.
Keeping that in mind, studies like the above could still
increase awareness about CD as well as the difficulties to
reach the most vulnerable population groups in
Germany as well as in other non-endemic European
countries and with this at least contribute to the detec-
tion of otherwise undetected cases of CD.
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